Final-Program-ATS-2023-AP.vp

172

MONDAY • MAY 22

P189 Predictors of Earlier PAH Combination Therapy: Findings From the Real-world in the US, Europe, and Japan/ D. Lautsch, North Wales, PA P190 PHederation - The Federated Network of Real-World Data Assets in Pulmonary Hypertension/ R.T. Zamanian, Stanford, CA P191 Long-term Ablation Outcomes of Atrial Flutter in Patients With Pulmonary Hypertension/ H. Zhang, Beijing, China

BASIC • CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

B59

BREAKING BAD: NEW DRUGS AND FORMULATIONS FOR PULMONARY HYPERTENSION AND RV FAILURE

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area B, Hall C (Lower Level)

BASIC • CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion 12:15-1:15 authors will be present for discussionwith assigned facilitators. P203 Longitudinal Use of Midodrine to Optimize Pulmonary Hypertension Therapies/ Z. Safdar, Houston, TX P204 Endothelin Receptor Antagonists (ERA) and Integrase Inhibitors: Competition or Cooperation?/ J.P.D. Silva Filho, Sao Paulo, Brazil P205 Use of Long-term Oxygen Therapy in Patients With Pulmonary Hypertension in Spain/ I. Blanco, Barcelona, Spain P206 Tolerability of Treprostinil Dry-powdered Inhaler in Patients With Pulmonary Hypertension Related to Fibrosing Interstitial Lung Disease at a Large Respiratory Referral Center/ M. Dalabih, Denver, CO P207 A First-in-Human Single/Multiple Ascending Dose Study of ANPA-0073, a Novel Small Molecule G-protein Biased Apelin Receptor Agonist, in Healthy Volunteers/ M. Bach, South San Francisco, CA P208 Inhaled Milrinone in Pulmonary Hypertension: A Systematic Review and Meta-analysis/ K. El Gharib, New York, NY P209 Study Design of the Decentralized EVOLVE Study Evaluating Real-world Use of Next Generation Infusion Pumps to Deliver Parenteral Treprostinil in Patients With Pulmonary Arterial Hypertension/ M.R. Sketch, Durham, NC P210 Right Ventricle Specific Therapies in Acute Respiratory Distress Syndrome: A Scoping Review/ S. Ganeriwal, Cleveland, OH P211 Therapeutic Potential Of ACE2-Ang-(1-7)-MAS Axis on Right Ventricular Remodeling in Pulmonary Hypertension/ Z.-K. Dai, Kaohsiung, Taiwan P212 A Phase I Clinical Trial Assessing the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of NTP42:KVA4, a Novel Thromboxane Receptor Antagonist, in Healthy Subjects/ B.T. Kinsella, Dublin, Ireland

B58

DON’T FORGET ABOUT THE BLOOD VESSELS! PULMONARY VASCULAR FUNCTION IN ACUTE LUNG INJURY

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion 12:15-1:15 authors will be present for discussionwith assigned facilitators. P193 Sod2 Is a Key Mechanistic Player in WWOX-mediated ARDS Resilience/ W. Chen, Chicago, IL P194 Metabolic Acidosis Does Not Increase Lung Permeability in Carbonic Anhydrase IX Knockout Mice/ R.P. Stevens, Mobile, AL P195 Sleep Fragmentation Results in Increased Vascular Permeability and Lung Injury Following Pneumonia/ L. Zheng, Baltimore, MD P196 UCHL1, a Deubiquitinating Enzyme, Augments Endothelial Cell Barrier Function in Radiation-induced Lung Injury/ Y. Epshtein, Chicago, IL P197 Functional Roles for CD26/DPP4 in LPS-induced Lung Injury in Mice/ S. Sato, Chiba, Japan P198 Smoking and Outcomes in Candidates for Liver Transplantation: PVCLD2/ C. Cecil, Philadelphia, PA P199 Pulmonary Embolism Induces Pneumonia-Like Lung Injury Beyond Pulmonary Infarction/ L. Zhao, Shenyang, China P200 Developmental Expression of Paternally Expressed Gene-3 Promotes Angiogenic Function in General Capillary Endothelial Cells From the Early Alveolar Lung/ M. Liu, Stanford, CA P201 Endothelial S-nitrosothiol Import via LAT1 Modulates Red Blood Cell Adhesion in the Mouse Lung/ H. Zhu, Durham, NC

ATS 2023 • Washington, DC